Skip to Main Content

Paper Details

COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs.
Br J Ophthalmol
51
2021
COVID-19, COVID-19 disease, MERS, Middle East respiratory syndrome, SARS, SARS-CoV, SARS-CoV-2, coronavirus, coronavirus 2, immunosuppressed, patients, people, severe acute respiratory syndrome coronavirus
COVID-19, Eye Diseases, Humans, Immunosuppression Therapy, Immunosuppressive Agents, Ophthalmology, Pharmaceutical Preparations, Practice Guidelines as Topic, SARS-CoV-2
Author NameAffiliation
Zheng Xian ThngNational Healthcare Group Eye Institute, Tan Tock Seng Hospital
Marc D de Smet
Cecilia S LeeUniversity of Washington
Vishali GuptaPostgraduate Institute of Medical Education and Research
Justine R SmithCollege of Medicine and Public Health, Flinders University
Peter McCluskeySydney Eye Hospital
Peter McCluskeySave Sight Institute
Jennifer E ThorneJohns Hopkins Wilmer Eye Institute
John H KempenMassachusetts Eye and Ear and Harvard Medical School
John H KempenMyungSung Christian Medical Center (MCM) Eye Unit, MCM General Hospital and Myung Sung Medical College
Manfred ZierhutUniversity of Tuebingen
Quan Dong NguyenByers Eye Institute, Stanford University
Carlos PavesioMoorfields Eye Hospital NHS Foundation Trust
Rupesh AgrawalNational Healthcare Group Eye Institute, Tan Tock Seng Hospital
Rupesh AgrawalMoorfields Eye Hospital NHS Foundation Trust
  • 1 - 15

Datasets

Release 1.2